 Brett Stevens
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 25 | 2025 | 630 | 3.890 |
Why?
| | Neoplastic Stem Cells | 15 | 2025 | 399 | 1.880 |
Why?
| | Myelodysplastic Syndromes | 4 | 2020 | 135 | 1.760 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 13 | 2025 | 227 | 1.380 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 1692 | 1.360 |
Why?
| | Proto-Oncogene Proteins c-cbl | 3 | 2014 | 12 | 1.000 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 801 | 0.990 |
Why?
| | Azacitidine | 8 | 2024 | 140 | 0.960 |
Why?
| | Sulfonamides | 11 | 2025 | 513 | 0.910 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.780 |
Why?
| | Flow Cytometry | 3 | 2020 | 1178 | 0.720 |
Why?
| | Multiple Myeloma | 4 | 2025 | 252 | 0.640 |
Why?
| | Hematopoietic Stem Cells | 2 | 2021 | 406 | 0.600 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 622 | 0.590 |
Why?
| | Salvage Therapy | 1 | 2019 | 142 | 0.580 |
Why?
| | Proto-Oncogene Proteins c-fyn | 2 | 2014 | 12 | 0.570 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 327 | 0.560 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 6 | 0.490 |
Why?
| | Mice, Inbred NOD | 7 | 2020 | 601 | 0.490 |
Why?
| | Leukocytosis | 1 | 2015 | 30 | 0.490 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 327 | 0.480 |
Why?
| | Clonal Evolution | 1 | 2015 | 45 | 0.470 |
Why?
| | Mice, SCID | 5 | 2020 | 367 | 0.460 |
Why?
| | Oxidative Phosphorylation | 6 | 2024 | 193 | 0.440 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2014 | 25 | 0.440 |
Why?
| | Computational Biology | 1 | 2019 | 644 | 0.440 |
Why?
| | Interferon Regulatory Factors | 3 | 2024 | 39 | 0.430 |
Why?
| | Proto-Oncogene Proteins c-myc | 3 | 2024 | 139 | 0.410 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 1079 | 0.410 |
Why?
| | Leukemia | 3 | 2020 | 240 | 0.400 |
Why?
| | Mutation | 3 | 2024 | 3958 | 0.400 |
Why?
| | Cell Proliferation | 4 | 2021 | 2475 | 0.390 |
Why?
| | Carrier Proteins | 1 | 2015 | 771 | 0.360 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2025 | 122 | 0.350 |
Why?
| | Nuclear Proteins | 1 | 2015 | 712 | 0.340 |
Why?
| | Glioblastoma | 1 | 2014 | 345 | 0.340 |
Why?
| | Neutrophils | 1 | 2015 | 1238 | 0.320 |
Why?
| | Neoplasm, Residual | 3 | 2024 | 133 | 0.290 |
Why?
| | Cell Self Renewal | 2 | 2019 | 56 | 0.290 |
Why?
| | Mice | 18 | 2025 | 17787 | 0.280 |
Why?
| | Fatty Acids | 3 | 2020 | 443 | 0.280 |
Why?
| | Stem Cells | 3 | 2020 | 594 | 0.280 |
Why?
| | Humans | 42 | 2025 | 137585 | 0.280 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1276 | 0.260 |
Why?
| | Animals | 21 | 2025 | 36940 | 0.250 |
Why?
| | Cell Line, Tumor | 8 | 2025 | 3412 | 0.250 |
Why?
| | Protein Kinase Inhibitors | 3 | 2025 | 916 | 0.250 |
Why?
| | Amino Acids | 2 | 2020 | 497 | 0.250 |
Why?
| | Ikaros Transcription Factor | 1 | 2024 | 24 | 0.220 |
Why?
| | Thalidomide | 1 | 2024 | 40 | 0.220 |
Why?
| | Ribosomes | 1 | 2025 | 186 | 0.210 |
Why?
| | Tumor Cells, Cultured | 4 | 2022 | 955 | 0.210 |
Why?
| | Finland | 1 | 2023 | 85 | 0.210 |
Why?
| | Uncertainty | 1 | 2023 | 128 | 0.200 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 26 | 0.190 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 433 | 0.190 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 412 | 0.190 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.190 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 48 | 0.180 |
Why?
| | Survival Rate | 3 | 2025 | 1972 | 0.180 |
Why?
| | Lipids | 1 | 2025 | 672 | 0.170 |
Why?
| | Trans-Activators | 2 | 2021 | 398 | 0.170 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 15 | 0.170 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 19 | 0.170 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 47 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2020 | 56 | 0.170 |
Why?
| | RNA Splicing Factors | 1 | 2020 | 53 | 0.170 |
Why?
| | Lipase | 1 | 2020 | 69 | 0.170 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 206 | 0.160 |
Why?
| | Oxidation-Reduction | 4 | 2019 | 1060 | 0.160 |
Why?
| | Mitochondria | 2 | 2024 | 948 | 0.160 |
Why?
| | Neoplasms | 1 | 2014 | 2671 | 0.160 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 172 | 0.160 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.160 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7635 | 0.160 |
Why?
| | Signal Transduction | 5 | 2022 | 5079 | 0.160 |
Why?
| | Lentivirus | 1 | 2019 | 56 | 0.160 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 39 | 0.150 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 17 | 0.150 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 226 | 0.150 |
Why?
| | Cytarabine | 1 | 2019 | 61 | 0.150 |
Why?
| | Histone Deacetylases | 1 | 2020 | 215 | 0.150 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 94 | 0.150 |
Why?
| | Aged | 9 | 2025 | 23961 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2020 | 200 | 0.150 |
Why?
| | Bone Marrow | 2 | 2020 | 286 | 0.150 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 257 | 0.150 |
Why?
| | Homeostasis | 2 | 2021 | 621 | 0.150 |
Why?
| | Calcium | 1 | 2024 | 1199 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2020 | 338 | 0.140 |
Why?
| | Cell Survival | 3 | 2022 | 1120 | 0.140 |
Why?
| | RNA Interference | 3 | 2014 | 469 | 0.140 |
Why?
| | Female | 17 | 2025 | 73304 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 900 | 0.140 |
Why?
| | Male | 13 | 2025 | 67762 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 204 | 0.140 |
Why?
| | Cation Transport Proteins | 1 | 2019 | 134 | 0.140 |
Why?
| | Stress, Physiological | 1 | 2021 | 443 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 648 | 0.140 |
Why?
| | Arthritis, Experimental | 1 | 2019 | 147 | 0.140 |
Why?
| | Repressor Proteins | 1 | 2020 | 427 | 0.130 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 194 | 0.130 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 197 | 0.130 |
Why?
| | Cells, Cultured | 3 | 2019 | 4193 | 0.130 |
Why?
| | Tumor Burden | 2 | 2016 | 309 | 0.130 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 434 | 0.130 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 56 | 0.130 |
Why?
| | Oncogene Proteins | 1 | 2016 | 59 | 0.120 |
Why?
| | HEK293 Cells | 2 | 2019 | 730 | 0.120 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 93 | 0.120 |
Why?
| | Gene Expression | 1 | 2020 | 1502 | 0.120 |
Why?
| | Methyltransferases | 1 | 2016 | 78 | 0.120 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 70 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 460 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 156 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 19 | 0.110 |
Why?
| | Cytokines | 3 | 2020 | 2085 | 0.110 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2014 | 48 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 317 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 399 | 0.110 |
Why?
| | Middle Aged | 7 | 2025 | 33479 | 0.110 |
Why?
| | Carmustine | 1 | 2014 | 50 | 0.110 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2014 | 73 | 0.110 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 136 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2024 | 15657 | 0.110 |
Why?
| | Dacarbazine | 1 | 2014 | 98 | 0.110 |
Why?
| | Prognosis | 4 | 2025 | 4030 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2031 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 327 | 0.100 |
Why?
| | Spheroids, Cellular | 1 | 2014 | 76 | 0.100 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2013 | 22 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1020 | 0.100 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 69 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5131 | 0.100 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2129 | 0.100 |
Why?
| | Inflammation | 2 | 2021 | 2837 | 0.100 |
Why?
| | Tamoxifen | 1 | 2013 | 202 | 0.100 |
Why?
| | Adaptation, Physiological | 1 | 2016 | 553 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1129 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 635 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1943 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2018 | 1164 | 0.090 |
Why?
| | Blotting, Western | 1 | 2014 | 1226 | 0.090 |
Why?
| | Blast Crisis | 2 | 2025 | 33 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5757 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1167 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2018 | 1208 | 0.080 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 50 | 0.080 |
Why?
| | Machine Learning | 2 | 2025 | 493 | 0.080 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2008 | 11 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 69 | 0.070 |
Why?
| | Young Adult | 3 | 2021 | 13209 | 0.070 |
Why?
| | Energy Metabolism | 3 | 2019 | 922 | 0.070 |
Why?
| | Protein Binding | 1 | 2014 | 2224 | 0.070 |
Why?
| | Fresh Water | 1 | 2008 | 57 | 0.070 |
Why?
| | Adult | 5 | 2025 | 37929 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 233 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4295 | 0.060 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 289 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2016 | 3015 | 0.060 |
Why?
| | Biodiversity | 1 | 2008 | 409 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 88 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2024 | 10811 | 0.050 |
Why?
| | Disease Progression | 2 | 2023 | 2757 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 76 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 622 | 0.050 |
Why?
| | Bacteria | 1 | 2008 | 858 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1062 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2020 | 34 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2253 | 0.040 |
Why?
| | Spliceosomes | 1 | 2020 | 48 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 46 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 194 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 171 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 82 | 0.040 |
Why?
| | Drug Synergism | 1 | 2020 | 382 | 0.040 |
Why?
| | Adolescent | 1 | 2019 | 21513 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 16 | 0.040 |
Why?
| | RNA Splicing | 1 | 2020 | 269 | 0.040 |
Why?
| | Protein Transport | 1 | 2020 | 445 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 288 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2167 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 191 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1396 | 0.040 |
Why?
| | Cell Cycle | 1 | 2021 | 601 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 5742 | 0.040 |
Why?
| | Apoptosis | 2 | 2018 | 2553 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 872 | 0.030 |
Why?
| | Biological Transport | 1 | 2018 | 418 | 0.030 |
Why?
| | Glutathione | 1 | 2019 | 356 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.030 |
Why?
| | Glycolysis | 1 | 2018 | 321 | 0.030 |
Why?
| | NADP | 1 | 2016 | 49 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 491 | 0.030 |
Why?
| | Gonads | 1 | 2016 | 23 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 460 | 0.030 |
Why?
| | CD36 Antigens | 1 | 2016 | 36 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 56 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 53 | 0.030 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 10 | 0.030 |
Why?
| | Sesquiterpenes | 1 | 2016 | 55 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 674 | 0.030 |
Why?
| | Lipolysis | 1 | 2016 | 46 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 257 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 350 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 828 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 518 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 318 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 72 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 79 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 276 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 202 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 1991 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 843 | 0.030 |
Why?
| | Recurrence | 1 | 2016 | 1060 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1430 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 506 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 145 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2426 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 434 | 0.020 |
Why?
| | New York | 1 | 2008 | 126 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2409 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4149 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2008 | 195 | 0.020 |
Why?
| | Geography | 1 | 2008 | 200 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2008 | 560 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2008 | 549 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 812 | 0.010 |
Why?
| | Prospective Studies | 1 | 2016 | 7604 | 0.010 |
Why?
| | Phylogeny | 1 | 2008 | 904 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2900 | 0.010 |
Why?
| | Child | 1 | 2020 | 21935 | 0.010 |
Why?
|
|
Stevens's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|